Description and pharmacological effect of the drug
“Egylok” is a synthetic agent used, in particular, for the treatment of arterial hypertension, prevention migraines. The main active substance of this drug is metoprolol tartrate. Egilok is produced in tablets with a dosage of 0.025 g, 0.05 g and 0.1 g in packs of 20, 30, 60.100 tablets. In the tablet form, the drug “Egylok Retard” is produced — with the same active and auxiliary substances. In a pack of 30 tablets dosage of 0.05 g and 0.1 g.
The drug is very quickly and almost completely (95 percent) absorbed from the gastrointestinal tract. Its bioavailability is 50 percent. In the treatment process, the rate of biostopnusty is 70 percent. Eating 20 to 40 percent contributes to increasing bioavailability of the drug. The active substance of aegilocus – metoprolol – is biotransformed in the liver. Metabolites of the drug are not pharmacologically active. 95 percent of the active substance of the drug is removed from the body within 72 hours, with urine. Approximately 5 percent of metoprolol remain unchanged. In this form they are excreted from the body.
Indications for the use of
“Egylok” are prescribed to patients with arterial hypertension (especially people over 60 years of age), using this drug alone or in complex therapy with other antihypertensive agents. It is necessary to take “Aegilocus” for secondary prevention of myocardial infarction, for prevention of angina attacks, for heart rate disorders — ventricular extrasystolia, najeludocular arrhythmia, hyperthyroidism. Prescribe the drug and for the prevention of migraines. Also “Egylok” is used in coronary heart disease,
Pharmacological action of
“Egylok” is a cardioselective beta-blocker exerting hypotensive effects, reducing the incidence of cardiac contractions, reducing the severity of angina and the incidence of attacks, contributes to the improvement of the patient’s physical condition. It is also possible to significantly reduce the risk of repeated myocardial infarction thanks to the action of “Aegilocus” Warns the occurrence of migraines. The doses indicated in the instruction have no effect on the peripheral arteries and smooth musculature of the bronchi.
Maximum action of the drug manifests within an hour and a half after taking. Approximately 5 percent of the active substance is excreted from the body with urine unchanged. The rest of the drug biotransforms in the liver. Therefore, people with liver pathology, disorders of its functions need to monitor the doctor and correct the dose.
Method of use and dose
The dosage of “Aegiloca” is prescribed to each patient individually, taking into account the state of his health and the presence of accompanying factors. For example, in arterial hypertension, the initial dose of the drug is 50 mg per day in one or two intake. If there is no effect or small results, it is recommended to increase the dosage, but not more than 200 mg per day. For patients suffering from angina, the recommended dose of the drug is 100-200 mg per day 1 or 2 times per day. A similar dose is also prescribed in najeludocular arrhythmias, as well as in extrasystolia. The drug should be taken twice a day (morning and evening). 100-200 mg a day twice a day – such is the dosage of the drug when prescribed for the prevention of secondary myocardial infarction, attacks migraines. Increasing the dose specified in the annotation is not recommended.
Diabetes patients need to constantly monitor their blood sugar levels.
When prescribing “Aegilocus” to patients with disorders of liver and kidney functions, a doctor is required This is necessary due to the ability of the drug to accumulate in the excretive organs.
Contraindications to the use of the drug
“Egilok” should not be prescribed to patients with sinus bradycardia with a heart rate of less than 60 beats per minute; AB-blockade second or third degree; sinoatrial blockade; peripheral circulation disorders; arterial hypotension (reduced blood pressure below 90-100 mmHg); high susceptibility components of the drug. In this case, it is necessary to replace the drug with any other remedy with similar effect.
During ingestion of “Aegilocus”, high fatigue, drowsiness, dizziness, depression, insomnia, reduced concentration of attention, nausea, vomiting, diarrhea, constipation, dry mouth, abdominal pain, heart failure. In rare cases, visual impairments, tinnitus, conjunctivitis, allergic reactions, redness of the skin, baldness, increased sweating, increased body weight can be noted. But in most cases, the drug is well tolerated.
“ Aegilocus” can cause diffuse, drowsiness, so it should be assigned with caution to people whose profession requires special attention.
During pregnancy, the use of aegilocus is possible only if the benefit to the mother’s body exceeds the risk to the fetus. It is necessary to monitor the condition of the fetus. After birth, monitoring of the newborn is also necessary to exclude arterial hypertension, respiratory oppression, bradycardia, blood sugar reduction. During pregnancy, “Egilok” is recommended to be replaced with a similar drug, but more sparing action.
Shelf life and storage conditions
Shelf life – 3 years.
Store at a temperature not exceeding 25°C in a dry place not accessible to children.